# Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC

> **NCT03623737** · PHASE2,PHASE3 · UNKNOWN · sponsor: **National Taiwan University Hospital** · enrollment: 248 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma
- Chemoradiation

## Interventions

- **DRUG:** neoadjuvant chemoradiation

## Key facts

- **NCT ID:** NCT03623737
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-01
- **Primary completion:** 2023-03-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 248 (ESTIMATED)
- **Last updated:** 2022-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03623737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03623737, "Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03623737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*